How You Can Participate in the Ataluren Ad Comm

The FDA has announced the scheduling of a September 28th Advisory Committee Meeting for PTC ’s therapy ataluren. Whether submitting written testimony and/or attending the Ad Comm in person, there are multiple ways for Duchenne community members in the U.S. and abroad to have an impact and share your personal experience with the Advisory Committee reviewing this product. Visit our blog to learn how you can participate.
Source: Parent Project Muscular Dystrophy - Category: Neurology Source Type: news